PROM1 and gastric cancer: However, the evidence to determine the clinical value of CD44 and CD133 remains insufficient, partially because much existing evidence is conflicting.[14–16] No study has compared the relationships between these 2 common CSC markers on gastric cancer cells and clinicopathological features or their impact on survival.